Joshua ElkingtonFounder and General Partner at Axial

Scientist Stories: Paul Carter, Genentech & Pioneer in Bispecifics and Antibody Engineering

Name: Scientist Stories: Paul Carter, Genentech & Pioneer in Bispecifics and Antibody Engineering
Uploaded: 2022-10-26T16:16:02+00:00
Duration: 1 min 25 s
Channel: Joshua Elkington
Description: In this monologue, Paul Carter, a scientist at Genentech, discusses the current state and future directions of antibody therapeutics. He emphasizes that…

26 Oct 2022 · 1 min

Watch on YouTube

1:25

In this monologue, Paul Carter, a scientist at Genentech, discusses the current state and future directions of antibody therapeutics. He emphasizes that while antibodies are well‑established as drugs, the key challenge now is to create better antibody medicines that improve patient outcomes and can compete commercially in crowded therapeutic areas. Carter highlights cancer immunotherapy as a major opportunity, encompassing both antibody‑based and targeted T‑cell approaches. He notes the rapid innovation across the industry, including diverse formats such as bispecific antibodies and non‑antibody scaffolds, and stresses the importance of staying up‑to‑date with scientific advances. Finally, he values conferences as venues for learning about new science and reconnecting with long‑standing colleagues.

Chapters

Hi, I'm Paul Carter. I work at Genentech. I'm involved in developing antibody therapeutics and new antibody technologies. I would say very broadly, antibodies are well established as drugs, and the challenge now is really to develop better antibody drugs to achieve a better outcome for patients. And from a commercial perspective, you're competing against lots of other companies typically going after the same indications. And so you have to be able to compete in the commercial sense as well. Well, I think one of the huge opportunities that obviously a lot of people are pursuing is in the area of cancer immunotherapy. And they're both kind of antibody-based approaches and targeted T-cell-based approaches. I think there's interesting science in many different areas. In coming to these meetings, I'm always amazed by the ingenuity of colleagues across industry in different formats, different applications of antibodies, bispecific antibodies, non-antibody scaffolds. There are many aspects. Certainly a very basic part is the science and really staying abreast of, of what's new. And it's also a great opportunity to, to meet up with colleagues, some of whom I've named for years or even decades.